Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXNASDAQ:BLPHNASDAQ:FCSCNASDAQ:INNTNASDAQ:SVRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.19$1.79$1.08▼$5.50$9.43M0.9616,965 shs3,902 shsBLPHBellerophon Therapeutics$0.06$0.05$0.03▼$11.15$660K0.6724,411 shs10,136 shsFCSCFibrocell Science$3.00$3.00$1.45▼$3.28$29.28M1.6778,673 shsN/AINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shsN/ASVRASavara$4.45+5.0%$4.93$1.78▼$5.70$585.75M0.77875,256 shs1.25 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%-1.65%-36.02%-55.01%-68.68%BLPHBellerophon Therapeutics+1.66%-3.68%-4.75%-9.84%-99.26%FCSCFibrocell Science0.00%0.00%0.00%0.00%0.00%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.89%SVRASavara+4.95%-7.10%-9.37%-7.29%+145.86%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABLPHBellerophon Therapeutics2.1848 of 5 stars3.00.00.04.83.20.00.6FCSCFibrocell ScienceN/AN/AN/AN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara3.0686 of 5 stars3.55.00.00.02.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/ABLPHBellerophon Therapeutics2.00Hold$2.003,536.36% UpsideFCSCFibrocell ScienceN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/ASVRASavara3.00Buy$8.2084.27% UpsideCurrent Analyst RatingsLatest AKTX, BLPH, FCSC, INNT, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.003/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/AFCSCFibrocell Science$350K83.66N/AN/A$0.98 per share3.06INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/ASVRASavaraN/AN/AN/AN/A$1.04 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)FCSCFibrocell Science-$10.28M-$1.45N/AN/AN/AN/A23.10%10.56%N/AINNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/ASVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)Latest AKTX, BLPH, FCSC, INNT, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/26/2024N/ABLPHBellerophon TherapeuticsN/A-$0.42-$0.42N/AN/AN/A3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.950.95BLPHBellerophon TherapeuticsN/A3.963.96FCSCFibrocell Science0.475.095.09INNTInnovate BiopharmaceuticalsN/A0.350.35SVRASavara0.1915.6615.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%BLPHBellerophon Therapeutics10.61%FCSCFibrocell Science36.72%INNTInnovate Biopharmaceuticals5.88%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%BLPHBellerophon Therapeutics5.20%FCSCFibrocell Science1.10%INNTInnovate Biopharmaceuticals7.90%SVRASavara4.58%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics97.92 million3.03 millionNot OptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableFCSCFibrocell Science199.76 millionN/AOptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableSVRASavaraN/A138.15 million131.82 millionOptionableAKTX, BLPH, FCSC, INNT, and SVRA HeadlinesSourceHeadlineSavara Inc. (SVRA) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com - April 25 at 8:08 PMSavara (NASDAQ:SVRA) Trading Down 6.6%marketbeat.com - April 24 at 6:51 PMSavara Inc (NASDAQ:SVRA) Shares Acquired by Jennison Associates LLCmarketbeat.com - April 24 at 7:27 AMJMP Securities Reiterates "Market Outperform" Rating for Savara (NASDAQ:SVRA)americanbankingnews.com - April 20 at 1:54 AMFYBR, BCRX and SABR are among after hour moversseekingalpha.com - April 20 at 1:53 AMSavara's (SVRA) Market Outperform Rating Reiterated at JMP Securitiesmarketbeat.com - April 18 at 2:21 PMSavara (NASDAQ:SVRA) Trading Down 3.9%marketbeat.com - April 17 at 12:20 PMSavara (NASDAQ:SVRA) Sees Large Volume Increasemarketbeat.com - April 15 at 1:54 PMVanguard Group Inc. Buys 789,249 Shares of Savara Inc (NASDAQ:SVRA)marketbeat.com - April 14 at 4:16 AMSavara Calls Out Haters!ghettoradio.co.ke - April 13 at 12:23 PMSavara (NASDAQ:SVRA) Shares Up 3.6%marketbeat.com - April 11 at 1:47 PMOptimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study Outcomesmarkets.businessinsider.com - April 11 at 8:38 AMSavara (NASDAQ:SVRA) Trading Up 2.6%marketbeat.com - April 4 at 12:45 AMDetails of Savara’s Upcoming Projectsghettoradio.co.ke - March 27 at 5:19 AMSavara Announces New Employment Inducement Grantbusinesswire.com - March 22 at 4:05 PMSavara: Why Sauti Sol had to take a break from each othermpasho.co.ke - March 19 at 4:25 AMSavara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trialmsn.com - March 13 at 1:33 PMFDA lifts partial hold on Nurix Phase 1 study for NX-2127msn.com - March 11 at 6:57 PMBuy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostimmarkets.businessinsider.com - March 11 at 1:57 PMSVRA Jul 2024 7.500 callfinance.yahoo.com - March 10 at 9:20 AMOptimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong Financialsmarkets.businessinsider.com - March 8 at 9:43 AMSVRA Stock Earnings: Savara Beats EPS for Q4 2023msn.com - March 7 at 11:08 PMSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Updatefinance.yahoo.com - March 7 at 6:08 PMBest penny stocks of March 2024usatoday.com - March 6 at 4:44 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Fibrocell ScienceNASDAQ:FCSCFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.